Wolfe Research Upgrades Stevanato Group (NYSE:STVN) to “Strong-Buy”

Stevanato Group (NYSE:STVN) was upgraded by stock analysts at Wolfe Research to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

STVN has been the subject of several other reports. Morgan Stanley lowered their price objective on Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating for the company in a research report on Friday, March 6th. Jefferies Financial Group set a $17.50 target price on Stevanato Group in a research note on Tuesday, February 10th. KeyCorp lowered their target price on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating for the company in a report on Thursday, March 5th. Citigroup dropped their price target on Stevanato Group from $32.00 to $26.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Finally, Weiss Ratings cut Stevanato Group from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy”.

Stevanato Group Trading Up 0.7%

NYSE:STVN opened at €18.92 on Monday. Stevanato Group has a 52 week low of €12.89 and a 52 week high of €28.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.11 and a current ratio of 1.63. The firm’s fifty day moving average is €16.08 and its 200-day moving average is €17.88. The firm has a market cap of $5.73 billion, a P/E ratio of 32.07, a P/E/G ratio of 1.74 and a beta of 0.78.

Stevanato Group (NYSE:STVN) last announced its earnings results on Friday, May 8th. The company reported €0.11 earnings per share for the quarter, missing analysts’ consensus estimates of €0.12 by (€0.01). The firm had revenue of €273.57 million for the quarter. Stevanato Group had a return on equity of 10.27% and a net margin of 11.76%.The firm’s revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.10 earnings per share. Equities analysts expect that Stevanato Group will post 0.68 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Glenmede Trust Co. NA lifted its stake in shares of Stevanato Group by 29.5% in the first quarter. Glenmede Trust Co. NA now owns 38,461 shares of the company’s stock valued at $529,000 after buying an additional 8,770 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Stevanato Group by 15.8% in the 1st quarter. Royal Bank of Canada now owns 421,696 shares of the company’s stock worth $5,798,000 after acquiring an additional 57,536 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Stevanato Group in the 1st quarter worth about $1,749,000. Sei Investments Co. lifted its position in Stevanato Group by 4.0% in the 1st quarter. Sei Investments Co. now owns 266,218 shares of the company’s stock valued at $3,661,000 after acquiring an additional 10,203 shares in the last quarter. Finally, Van Berkom & Associates Inc. boosted its stake in Stevanato Group by 2,944.2% during the 1st quarter. Van Berkom & Associates Inc. now owns 170,994 shares of the company’s stock valued at $2,351,000 after purchasing an additional 165,377 shares during the last quarter.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.